Australia’s Therapeutic Goods Administration (TGA) has approved a new treatment for early Alzheimer’s disease, called lecanemab, marketed under the brand name Leqembi. This decision...
A recent investigation has unveiled significant concerns surrounding the use of unapproved medicinal cannabis in Australia, with over 615 adverse events reported to the...
Authorities in Australia are investigating a significant increase in adverse event reports associated with the ADHD medication Vyvanse. The Therapeutic Goods Administration (TGA) has...
Reports of adverse events linked to the ADHD medication Vyvanse have surged dramatically in Australia this year, prompting an investigation by the Therapeutic Goods...